Health Discovery Corporation (OTCBB: HDVY), a molecular diagnostics company specializing in personalized medicine, announced today that its scientific paper entitled “A Four-Gene Expression Signature for Prostate Cancer Cells Consisting of UAP1, PDLIM5, IMPDH2, and HSPD1” has successfully completed the peer review process and has been approved for publication in the August issue of UroToday International Journal. This publication demonstrates the clinical validity of the four-gene prostate cancer test for identifying clinically significant prostate cancer licensed for commercialization by HDC to Abbott (NYSE: ABT), Quest Diagnostics (NYSE: DGX), and Clarient (NasdaqCM: CLRT).

UroToday International Journal® is an open access, peer-reviewed, urology and urologic oncology publication. The most widely accessible online urology publication in the field, UroToday International Journal® publishes state of the art reviews, original research papers, mini reports, rapid communications and more, in all fields of urology and has published articles from authors in 22 countries from 4 different continents. This International Urology Journal reaches over 18,000 subscribers and many more online readers. The Editorial Board of UroToday International Journal® strives to provide rapid publication of important manuscripts to the widest possible audience worldwide.

“We are very pleased to have the validated scientific results of our new four-gene prostate cancer test peer reviewed and accepted for publication by this prestigious and internationally recognized urology journal,” said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “The HDC four-gene prostate cancer test for clinically significant prostate cancer accepted for publication in UroToday International Journal® is the crux of our recent worldwide license agreements with our commercialization partners including Abbott, Quest Diagnostics and Clarient.” Dr. Barnhill continued “Having a peer reviewed medical publication should greatly assist our commercialization partners in their efforts to provide validated scientific results to physicians worldwide wanting to provide this new novel prostate cancer test to their patients, especially timely in light of the recent negative press regarding the poor performance of the PSA test for prostate cancer.”

About Health Discovery Corporation

Savannah-based Health Discovery Corporation (OTCBB: HDVY) is uniquely positioned in the field of personalized medicine.